These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 18392338)

  • 1. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).
    Rota E; Bazzan M; Fantino G
    Thromb Haemost; 2008 Apr; 99(4):779-81. PubMed ID: 18392338
    [No Abstract]   [Full Text] [Related]  

  • 2. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia.
    Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature].
    Franke J; Schaeper O; Kayser R; Mahlfeld K
    Unfallchirurg; 2003 Jan; 106(1):77-81. PubMed ID: 12552397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT.
    Warkentin TE; Sheppard JA; Manheim JC
    Thromb Haemost; 2014 Dec; 112(6):1319-22. PubMed ID: 25319237
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of heparin-induced thrombocytopenia with fondaparinux.
    Harenberg J; Jörg I; Fenyvesi T
    Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke.
    Salem M; Elrefai S; Shrit MA; Warkentin TE
    Thromb Haemost; 2010 Nov; 104(5):1071-2. PubMed ID: 20806120
    [No Abstract]   [Full Text] [Related]  

  • 8. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
    Lobo B; Finch C; Howard A; Minhas S
    Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
    Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced thrombocytopenia associated with fondaparinux.
    Warkentin TE; Maurer BT; Aster RH
    N Engl J Med; 2007 Jun; 356(25):2653-5; discussion 2653-5. PubMed ID: 17582083
    [No Abstract]   [Full Text] [Related]  

  • 11. A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals.
    Spinler SA
    Ann Pharmacother; 2009 Sep; 43(9):1519-21. PubMed ID: 19690223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia following hip and knee arthroplasty.
    Craik JD; Cobb AG
    Br J Haematol; 2013 Apr; 161(2):255-61. PubMed ID: 23406088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism.
    Prescrire Int; 2003 Feb; 12(63):3-5. PubMed ID: 12602371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparins, low-molecular-weight heparins, and pentasaccharides.
    Dinwoodey DL; Ansell JE
    Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-induced thrombocytopenia after liver transplantation.
    Kaneko J; Sugawara Y; Tamura S; Togashi J; Matsui Y; Makuuchi M
    Transplant Proc; 2008 Jun; 40(5):1518-21. PubMed ID: 18589141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781).
    Schindewolf M; Lindhoff-Last E
    Thromb Haemost; 2008 Jul; 100(1):168-9; author reply 169-70. PubMed ID: 18612559
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.